Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2023 02:00 ET | Source: argenx SE

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

$329 million in third quarter global net product salesOn track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host...
October 24, 2023 01:00 ET | Source: argenx SE

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

October 24, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
September 21, 2023 01:00 ET | Source: argenx SE

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0001) showing 68% of VYVGART-treated...
September 15, 2023 01:00 ET | Source: argenx SE

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV)...
August 30, 2023 01:00 ET | Source: argenx SE

argenx to Present at Upcoming Investor Conferences

August 30, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
July 27, 2023 01:00 ET | Source: argenx SE

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

$269 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART® Hytrulo now available in the U.S. with first vials shipped in JulyGlobal VYVGART expansion...
July 24, 2023 16:30 ET | Source: argenx SE

argenx announces closing of global offering

Regulated information – Inside information July 24, 2023, 4:30 PM ETJuly 24, 2023, 10:30 PM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
July 20, 2023 01:00 ET | Source: argenx SE

argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

July 20, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
July 19, 2023 17:58 ET | Source: argenx SE

argenx announces full exercise of underwriters’ option to purchase additional ADSs

Regulated information — Inside information July 19, 2023, 11:58 PM CETJuly 19, 2023, 5:58 PM ET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
July 18, 2023 21:30 ET | Source: argenx SE

argenx raises $1.1 billion in gross proceeds in a global offering

Regulated information — Inside information July 18, 2023, 9:20 PM ET July 19, 2023, 3:20 AM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology...